Board of Governors of the Federal Reserve System, July 10, 1987.

William W. Wiles,

Secretary of the Board.

[FR Doc. 87-16084 Filed 7-15-87; 8:45 am]

BILLING CODE 6210-01-M

Formations of; Acquisitions by; and Mergers of Bank Holding Companies; Allegheny Valley Bancorp, Inc., et al.

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than August 7, 1987.

A. **Federal Reserve Bank of Cleveland** (John J. Wixted, Jr., Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. *Allegheny Valley Bancorp, Inc.*, Pittsburgh, Pennsylvania; to become a bank holding company by acquiring 100 percent of the voting shares of Allegheny Valley Bank of Pittsburgh, Pittsburgh, Pennsylvania.

B. **Federal Reserve Bank of Atlanta** (Robert E. Heck, Vice President) 104 Marietta Street, NW., Atlanta, Georgia 30303:

1. *Security National Corporation*, Maitland, Florida; to become a bank holding company by acquiring 80 percent of the voting shares of Security National Bank of America, Maitland, Florida.

C. **Federal Reserve Bank of Chicago** (David S. Epstein, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *First Midwest Corporation of Delaware*, Elmwood Park, Illinois; to acquire 100 percent of the voting shares of State Bank of Union, Union, Illinois. Comments on this application must be received by August 6, 1987.

D. **Federal Reserve Bank of St. Louis** (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *First Illinois Bancorp, Inc., Employee Stock Ownership Plan and Trust*, East St. Louis, Illinois; to become a bank holding company by acquiring up to 40 percent of the voting shares of First Illinois Bancorp, Inc., East St. Louis, Illinois, and thereby indirectly acquire First Illinois Bank, East St. Louis, Illinois.

In connection with this application, First Illinois Bancorp, Inc., East St. Louis, Illinois, has applied to acquire 100 percent of the voting shares of Lindell Trust Company, St. Louis, Missouri.

E. **Federal Reserve Bank of Kansas City** (Thomas M. Hoenig, Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Community Bancshares of Chanute, Inc.*, Chanute, Kansas; to become a bank holding company by acquiring 100 percent of the voting shares of Community National Bank, Chanute, Kansas, a *de novo* bank. Comments on this application must be received by August 3, 1987.

2. *Riley County Bancshares, Inc.*, Riley, Kansas; to become a bank holding company by acquiring 97 percent of the voting shares of Riley State Bank, Riley, Kansas, which acts as agent for the sale of credit related insurance.

Board of Governors of the Federal Reserve System, July 9, 1987.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 87-16085 Filed 7-15-87; 8:45 am]

BILLING CODE 6210-01-M

Application to Engage de Novo in Permissible Nonbanking Activities; First Independent Investment Group, Inc.

The company listed in this notice has filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweight possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of intererts, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than July 30, 1987.

A. **Federal Reserve Bank of San Francisco** (Harry W. Green, Vice President) 101 Market Street, San Francisco, California 94105:

1. *First Independent Investment Group, Inc.*, Vancouver, Washington; to engage *de novo* in permitted credit insurance activities which include acting as underwriter, agent, or broker for life insurance, disability insurance and involuntary unemployment insurance directly related to extensions of credit made by Application and its subsidiaries pursuant to § 225.25(b)(8) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, July 9, 1987.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 87-16086 Filed 7-15-87; 8:45 am]

BILLING CODE 6210-01-M

Acquisitions of Shares of Banks or Bank Holding Companies; Change in Bank Control

The notificants listed below have

applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. Once the notices have been accepted for processing, they will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than July 30, 1987.

A. **Federal Reserve Bank of Chicago** (David S. Epstein, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Charles S. Gaskill,* Chicago Heights, Illinois; to acquire 4.36 percent of the voting shares of Olympia Bancorporation, Inc., Chicago Heights, Illinois, and thereby indirectly acquire Heritage/Olympia Bank, Chicago Heights, Illinois.

2. *John S. Koza,* Iowa City, Iowa, to acquire .079 percent of the voting shares of ISB Financial Corp., Iowa City, Iowa.

B. **Federal Reserve Bank of Kansas City** (Thomas M. Hoenig, Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Raymond J. Herrick,* Fowler, Colorado; H. Ben Weindling, Pueblo, Colorado; and Geoffrey O. Burney, Rocky Ford, Colorado; to acquire 26.3 percent of the voting shares of First Fowler Bancorp, Inc., Fowler, Colorado, and thereby indirectly acquire First National Bank of Fowler, Fowler, Colorado.

C. **Federal Reserve Bank of Dallas** (W. Arthur Tribble, Vice President) 400 South Akard Street, Dallas, Texas 75222:

1. *Meto Miteff,* Thompson E. Purvis, Jr., and J. Howard Shelton, all of Fort Worth, Texas; to acquire 30.15 percent of the voting shares of Tarrant Bancshares, Inc., Fort Worth, Texas, and thereby indirectly acquire Tarrant Bank, Fort Worth, Texas.

Board of Governors of the Federal Reserve System, July 9, 1987.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 87-16087 Filed 7-15-87; 8:45 am]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 87F-0206]

Filing of Food Additive Petition; Sun Chemical Corp.

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Sun Chemical Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a polymer prepared from urea, ethanedial, formaldehyde, and propionaldehyde, for use as a starch and protein reactant in coatings for paper and paperboard intended to contact dry food.

FOR FURTHER INFORMATION CONTACT: Andrew D. Laumbach, Center for Food Safety and Applied Nurtition (HFF-335), Food and Drug Administration, 200 C Street, SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 7B4006) has been filed by Sun Chemical Corp., P.O. Box 70, Chester, SC 29706, proposing that § 176.180 *Components of paper and paperboard in contact with dry food* (21 CFR 176.180) be amended to provide for the safe use of a polymer prepared from urea, ethanedial, formaldehyde, and propionaldehyde, for use as a starch and protein reactant in coatings for paper and paperboard intended to contact dry food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: July 8, 1987.

Sanford A. Miller,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87-16097 Filed 7-15-87; 8:45 am]

BILLING CODE 4160-01-M

Advisory Committees; Meetings; Dental Devices Panel et al.

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

Meetings: The following advisory committee meetings are announced:

Dental Devices Panel

Date, time, and place. August 27, 9 a.m., Room 337A-339A, Hubert H. Humphrey Bldg., 200 Independence Avenue, SW., Washington, DC.

Type of meeting and contact person. Open public hearing, 9 a.m. to 10 a.m.; open committee discussion, 10 a.m. to 1 p.m.; Dr. Gregory Singleton, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 8757 Georgia Avenue, Silver Spring, MD 20910, 301-427-7555.

General function of the committee. The committee reviews and evaluates available data on the safety and effectiveness of devices and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before July 27, and submit a copy of the presentation, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss a premarket approval application for a saliva-stimulating device.

Fertility and Maternal Health Drugs Advisory Committee

Date, time, and place. August 27 and 28, 9 a.m., Lister Hill Auditorium, National Library of Medicine, 8600 Rockville Pike, Bethesda, MD.

Type of meeting and contact person. Open public hearing, August 27, 9 a.m. to 10 a.m. unless public participation does not last that long; open committee discussion, 10 a.m. to 5 p.m.; open committee discussion, August 28, 9 a.m. to 5 p.m.; Philip A. Corfman, Center for Drugs and Biologics (HFN-810), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-3510.

General function of the committee. The committee reviews and evaluates

available data on the safety and effectiveness of marketed and investigational prescription drugs for use in obstetrics and gynecology.

Agenda—Open public hearing. Interested persons requesting to present data, information, or views, orally or in writing, on issues pending before the committee should notify the contact person.

Open committee discussion. On August 27, the committee will discuss World Health Organization (WHO) Guidelines for toxicological evaluation of steroid contraceptives. On August 28, the committee will discuss WHO Guidelines for clinical trials and postmarketing surveillance of steroid contraceptives.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (Subpart C of 21 CFR Part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's concludion, if time permits, at the chairperson's discretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contact person the approximate time of discussion.

Details on the agenda, questions to be addressed by the committee, and a current list of committee members are available from the contact person before and after the meeting. Transcripts of the open portion of the meeting will be available from the Freedom of Information Office (HFI–35), Food and Drug Administration, Room 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, Room 4–62, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting will be available from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a) (1) and (2) of the Federal Advisory Committee Act (Pub. L. 92–463, 86 Stat. 770–776– (5 U.S.C. App. I)), and FDA's regulations (21 CFR Part 14) on advisory committees.

Dated: July 9, 1987.

John M. Taylor,

Associate Commissioner for Regualtory Affairs.

[FR Doc. 87–16098 Filed 7–15–87; 8:45 am]

BILLING CODE 4160–01–M

Advisory Committee Meeting; Amendment of Notice

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is amending an advisory committee meeting notice of the Radiologic Devices Panel to reflect a change in location of the Panel's meeting scheduled July 27, 1987. Notice of the meeting was published in the **Federal Register** of June 12, 1987 (523 FR 22536). The meeting location has been changed from FDA's Center for Devices and Radiological Health, 12720 Twinbrook Parkway, Rockville, MD, to Conference Rm. D, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD, to accommodate a larger audience.

FOR FURTHER INFORMATION CONTACT: Robert Phillips, Center for Devices and Radiological Health (HFZ–430), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301–427–7514.

Dated: July 9, 1987.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 87–16099 Filed 7–15–87; 8:45 am]

BILLING CODE 4160–01–M

Advisory Committee Meeting; Amendment; General and Plastic Surgery Devices Panel

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is amending an advisory committee meeting notice of the General and Plastic Surgery Devices Panel to reflect changes in location and in the open committee discussion agenda. Notice of the meeting was published in the **Federal Register** of June 17, 1987 (52 FR 23082). The location and agenda are revised as follows:

Date, time, and place. August 28, 9 a.m., Auditorium, Health and Human Services North Bldg., 330 Independence Ave. SW., Washington, DC.

Open committee discussion. The committee will discuss a reclassification petition for gut surgical sutures (Docket No. 87P–0144) and a reclassification petition for absorbable poly (-glycolide/lactide (the family of homopolymers and copolymers of glycolide and/or L-lactide)) surgical sutures (Docket No. 87P–0161).

FOR FURTHER INFORMATION CONTACT: Paul F. Tilton, Center for Devices and Radiological Health (HFZ–410), Food and Drug Administration, 8757 Georgia Avenue, Silver Spring, MD 20910, 301–427–7156.

Dated: July 9, 1987.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 87–16100 Filed 7–15–87; 8:45 am]

BILLING CODE 4160–01–M